Agonist efficacy is a measure of how well an agonist can stimulate a response system linked to a receptor. Efficacy can be assessed in functional assays and various parameters (E max bound rather than the rate of binding.
Introduction
The actions of drugs at receptors depend on two events: the binding of the drug to the receptor and the response triggered by the drug at the receptor and in the associated tissue. The binding of the drug is reflected in the affinity with which the drug binds to the receptor. The ability of the drug to alter the activity of signalling systems linked to the receptor is often referred to as 'efficacy' and is reflected in differences in the extent and potency of the response. We can envisage a scale of efficacy from positive for agonists to negative for inverse agonists with neutral antagonists having zero efficacy. In this article, I shall consider methods for assessing efficacy and the mechanisms underlying efficacy for the GPCRs (Gprotein-coupled receptors). I shall restrict discussion to the GPCRs owing to their importance as targets for drug action.
Efficacy and its measurement
It is very important to understand and quantify the efficacy of drug action as this has an important bearing on drug action. For example, several drugs with very low, but positive, efficacy (partial agonists) have been introduced recently and have been found to have useful therapeutic properties. Examples here are buprenorphine, used for opiate addiction, buspirone used for anxiety and aripiprazole used for schizophrenia [1] . It seems that the very low agonist efficacy expressed by these drugs is important for their actions, and so systems that can define this efficacy are required. As efficacy refers to the functional effects of a drug, it must be defined using functional tests. The effects of a set of drugs are therefore tested in a concentration-response experiment using a suitable functional response linked to the receptor. Responses used in the past have typically been intact tissue responses such as smooth muscle contraction, but more recently, second messenger assays, e.g. cAMP and Ca 2+ , have been widely used. Newer biophysical assays for changes in receptor conformation (see, e.g., [2] ) are showing promise as well. For agonists, several measures of efficacy are then accessible from this kind of experiment. First, the maximal effects (E max ) of the drugs can be determined. Comparisons of the E max values for a set of drugs provides a useful measure of relative efficacy, but this measure fails where the drugs produce a full (100%) response in the test system. For drugs that produce a full response, which would be termed full agonists, it will be impossible to differentiate differences in relative efficacy and other measures are required. One such measure is the K A /EC 50 ratio [3] [4] [5] . This ratio provides an estimate of the extent to which the agonist response curve is shifted away from the agonist-binding curve. EC 50 represents the concentration of agonist that produces a half-maximal response and K A is the dissociation constant for agonist binding to the receptors (also the concentration of agonist that occupies half the receptors). The K A /EC 50 ratio provides a good estimate of relative efficacy for agonists with moderate to full efficacy, but approaches unity for the weaker agonists and so provides little discrimination in this efficacy range.
The two measures may be combined to produce the parameter E max · K A /EC 50 . This provides a continuous measure of efficacy over the full range of agonist efficacy (P.G. Strange, unpublished work, and see also [6] ) and so is a very useful parameter. When it is used to analyse real data in the literature, it also provides an excellent measure of efficacy ( Figure 1 ). azolines and phenylethylamines at α 1 adrenoceptors were used [26] . E max · K A /EC 50 was calculated and compared with functional relative efficacy values determined using occupancy-response curves. Values were expressed as fractions of values for adrenaline. A good correlation (r 2 = 0.90) between the two parameters is seen.
In vitro systems to measure agonist efficacy: the [ 35 S]GTP[S] (guanosine 5 -[γ -[ 35 S]thio]triphosphate)-binding assay
Whereas drug actions at many receptors can be assayed using functional tissue responses it is useful to use in vitro tests based on cell-free preparations of receptors, e.g. expressed in recombinant cells. One very popular assay is the [ 35 S]GTP[S]-binding assay (see, e.g., [7] ). This assay takes advantage of the normal G-protein cycle associated with GPCRs [8] . In the Gprotein cycle, the inactive G-protein (G) with GDP bound is converted into the active G-protein by combination with the agonist-occupied receptor (AR) to form the ternary complex ARG · GDP. In this complex, GDP release is facilitated and GTP binds to activate the G-protein. Dissociation of the Gprotein into α · GTP and βγ subunits occurs, and these alter effector activity, e.g. adenylate cyclase. [16, 18] .
NPA, N-propylnorapomorphine; (−)-3-PPP, S-(−)-3-(3-hydroxyphenyl)-N-propylpiperidine hydrochloride; UH-232, cis-(+)-5-methoxy-1-methyl-2-(di-N-propyl-

amino)tetralin;
AJ-76, (1S,2R)-cis-5-methoxy-1-methyl-2-(Npropylamino)tetralin.
The assay has been used for a number of GPCRs including opiate [11] , cannabinoid [12] , muscarinic acetylcholine [13] , CCR5 chemokine [14] and we have been using it to profile ligands at the D 2 dopamine receptor [3, 4, [15] [16] [17] . On the basis of concentration-response curves for a range of agonists and using E max values, we have defined a scale of efficacy (Figure 2) . The assay can be rather insensitive for defining responses of low-efficacy partial agonists or inverse agonists, and these may appear as antagonists in the normal assay configuration. We have shown, however, that, by substituting NMDG (N-methyl-D-glucamine) for the standard 100 mM Na + ions in the assay, the detection of partial agonism is improved considerably [18] , and additional removal of GDP improves detection of inverse agonists for the D 2 dopamine receptor [19] . For other GPCRs, inverse agonism may be detected under normal assay conditions, e.g. the 5-HT 1A (5-hydroxytryptamine 1A receptor) [20] , and this may depend on the level of constitutive activation of the receptor concerned.
Nevertheless, it is important to ask whether the relative efficacy values determined using this assay reflect relative efficacy values in other assays, including in vivo assays. This requires that we compare efficacy values in different assays for one receptor. There are actually very few sets of data that enable this comparison to be performed. For the D 2 dopamine receptor, I have compared data for the E max values for a range of ligands in [
35 S]GTP[S]-binding assays ( Figure 2 ) and in electrophysiology assays [21] . There is some agreement between the two sets of data (Figure 3 ), but the range of 
Mechanisms underlying the [ 35 S]GTP[S]-binding assay
The [
35 S]GTP[S]-binding assay is typically run as a single time point assay and is treated as a ligand-binding assay (see above). As a result, certain assumptions are made about the assays which may not be justified. In fact, the assay is a kinetic assay that is not at equilibrium under normal conditions. This is seen clearly in experiments where the time course of [ 35 S]GTP[S] binding is examined [15] . [23, 24] , and, under these conditions, the corresponding rate of GTP binding will be very high, and other steps in the G-protein cycle will be rate-determining.
There is then the question of how agonists affect this time course, as this is the basis of the use of this assay for assessing agonist efficacy. When a range of agonists of different efficacies was tested, it was found that different agonists lead to different maximal levels of to the ARG ternary complex, this could be via stabilization by the agonist of different amounts of ARG or by stabilizing ARG species with different affinities. We have not examined these possibilities in the present system, but, for other GPCRs, different agonists have effects on both the amount and affinity of ARG [11, 25] .
In conclusion, by studying the [ 35 S]GTP[S]-binding assay in this way, we have learnt about the mechanistic basis of the assay. This leads to greater clarity in the use of the assay as well as a greater understanding of the G-protein cycle and how it is regulated by agonists.
